| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
GMAB
Genmab
|
Jul 02, 2025 | HOLD |
Buy
+38.3% avg upside
26 analysts
|
$25.00
1.08% Downside
|
+29.8% |
|
ASND
Ascendis Pharma
|
Jun 23, 2025 | BUY |
Strong Buy
+17.0% avg upside
24 analysts
|
$250.00
8.37% Upside
|
+27.0% |
|
GB:0QW0
arGEN X
|
Jun 20, 2025 | BUY |
Strong Buy
-24.9% avg upside
24 analysts
|
$650.00
15.51% Downside
|
· |
|
AXSM
Axsome Therapeutics
|
Jun 19, 2025 | BUY |
Strong Buy
-10.5% avg upside
28 analysts
|
$190.00
24.16% Downside
|
+150.2% |
|
RXRX
Recursion Pharmaceuticals
|
Jun 17, 2025 | HOLD |
Buy
+146.1% avg upside
12 analysts
|
$5.00
54.78% Upside
|
-35.7% |
|
LYEL
Lyell Immunopharma
|
Jun 16, 2025 | HOLD |
Buy
+96.2% avg upside
10 analysts
|
— | +17.7% |
|
FHTX
Foghorn Therapeutics
|
Jun 12, 2025 | HOLD |
Strong Buy
+187.5% avg upside
17 analysts
|
$4.00
3.55% Downside
|
-5.7% |
|
ZBIO
Zenas BioPharma, Inc.
|
Jun 11, 2025 | BUY |
Strong Buy
+102.2% avg upside
11 analysts
|
$35.00
77.03% Upside
|
+46.7% |
|
SDGR
Schrodinger
|
Jun 10, 2025 | HOLD |
Strong Buy
+79.8% avg upside
14 analysts
|
$31.00
96.76% Upside
|
-45.9% |
|
INCY
Incyte
|
Jun 03, 2025 | HOLD |
Buy
+1.0% avg upside
47 analysts
|
$68.00
30.86% Downside
|
+46.0% |
|
KYMR
Kymera Therapeutics
|
Jun 03, 2025 | BUY |
Strong Buy
+8.9% avg upside
36 analysts
|
$79.00
12.69% Downside
|
+68.0% |
|
BMRN
BioMarin Pharmaceutical
|
May 29, 2025 | BUY |
Strong Buy
+72.8% avg upside
52 analysts
|
$105.00
92.07% Upside
|
-2.1% |
|
IRON
Disc Medicine
|
May 22, 2025 | BUY |
Strong Buy
+20.2% avg upside
21 analysts
|
$85.00
19.99% Upside
|
+39.1% |
|
ARQT
Arcutis Biotherapeutics
|
May 22, 2025 | BUY |
Strong Buy
+49.6% avg upside
14 analysts
|
$19.00
27.49% Downside
|
+52.7% |
|
CMPS
COMPASS Pathways
|
May 15, 2025 | BUY |
Strong Buy
+63.6% avg upside
18 analysts
|
$17.00
35.60% Upside
|
+162.5% |
|
ABSI
AbSci
|
May 15, 2025 | BUY |
Strong Buy
+36.3% avg upside
18 analysts
|
$7.00
5.62% Downside
|
+73.3% |
|
CERT
Certara
|
May 12, 2025 | HOLD |
Buy
+133.5% avg upside
21 analysts
|
$16.00
188.78% Upside
|
-58.0% |
|
LEGN
Legend Biotech
|
Mar 17, 2025 | BUY |
Strong Buy
+140.3% avg upside
27 analysts
|
$80.00
186.40% Upside
|
-51.1% |
|
ARGX
Argenx Se
|
Mar 05, 2025 | BUY |
Strong Buy
-15.9% avg upside
46 analysts
|
$715.00
18.60% Downside
|
+14.4% |
|
ABVX
Abivax SA Sponsored ADR
|
Jan 29, 2025 | HOLD |
Strong Buy
+20.7% avg upside
15 analysts
|
$12.00
87.93% Downside
|
+1834.2% |
|
SANA
Sana Biotechnology
|
Jan 10, 2025 | BUY |
Strong Buy
+214.8% avg upside
14 analysts
|
$12.00
281.03% Upside
|
+24.6% |
|
TCRX
TScan Therapeutics
|
Dec 11, 2024 | BUY |
Strong Buy
+823.9% avg upside
12 analysts
|
$14.00
1421.83% Upside
|
-65.3% |
|
HALO
Halozyme
|
Oct 03, 2024 | BUY |
Strong Buy
-13.7% avg upside
20 analysts
|
$64.00
6.62% Downside
|
+14.1% |
|
ONC
BeOne Medicines
|
Aug 26, 2024 | BUY |
Strong Buy
+28.4% avg upside
28 analysts
|
$307.00
13.70% Upside
|
+55.1% |
|
RGNX
RegenXBio
|
Jun 13, 2024 | BUY |
Strong Buy
+381.4% avg upside
22 analysts
|
$42.00
438.51% Upside
|
-29.1% |
|
EVLO
Evelo Biosciences
|
Aug 29, 2023 | HOLD |
Buy
+4499999900.0% avg upside
5 analysts
|
$10.00
999999899.94% Upside
|
· |
|
TIL
Instil Bio
|
Dec 09, 2022 | HOLD |
Buy
+343.4% avg upside
8 analysts
|
$40.00
433.38% Upside
|
-65.2% |
|
PROK
ProKidney
|
Nov 10, 2022 | HOLD |
Buy
+260.7% avg upside
12 analysts
|
$13.00
610.37% Upside
|
-85.0% |
|
TBPH
Theravance Biopharma
|
Jul 25, 2022 | SELL |
Buy
+12.2% avg upside
18 analysts
|
$10.00
39.67% Downside
|
-3.2% |
|
DBVT
DBV Technologies SA - American
|
Aug 05, 2020 | HOLD |
Strong Buy
+55.4% avg upside
15 analysts
|
$2.00
87.22% Downside
|
+89.9% |
|
COGT
Cogent Biosciences
|
Mar 03, 2020 | HOLD |
Strong Buy
+7.1% avg upside
26 analysts
|
$2.00
94.30% Downside
|
+284.0% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.